Definitive Contract 75N93024C00019
Award Date
7/1/24
Potential Completion Date
6/30/27
Potential Value
$2M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Neovaxsyn Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Ames, IA 50011, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Neovaxsyn Inc., a minority-owned small disadvantaged business, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services. The $300,000 firm fixed-price contract supports the development of a next-generation immunoprevention platform against HIV-1, with a final completion date of October 31, 2025. The contract was awarded under the Small Business Innovation Research (SBIR) program, which...
This is a $300,000 firm fixed price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Neovaxsyn Inc., a minority-owned small disadvantaged business. The contract is for research and development to utilize nanoparticles to deliver MPER-based immunogens and elicit broadly neutralizing antibodies against the HIV-1 virus in order to develop a protective vaccine. This contract was awarded under the Small...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Neovaxsyn Inc., a minority-owned small disadvantaged business located in Ames, Iowa. The $300,000 firm-fixed-price contract supports the development of innovative HIV/AIDS vaccine technologies, including the use of nanoparticle delivery systems and strategies to induce broadly...
This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases, valued at $299,999, was awarded to Neovaxsyn Inc. to develop a protective HIV vaccine utilizing gold nanoparticles to elicit broadly neutralizing antibodies against the fusion peptide of HIV-1 GP41. The contract was awarded under the Small Business Innovation Research Program Phase I solicitation, which sought proposals for research...
This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will...
This is a $599,999 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Parabon NanoLabs, Inc., a small business. The objective of the contract is to develop a DNA-based HIV vaccine that will stimulate production of broadly neutralizing antibodies against the HIV-1 envelope protein trimer antigen. This is a Phase I Small Business Innovation Research (SBIR) contract under the...
This $299,040 firm-fixed-price Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective is to design and synthesize a new PLGA-based nanoparticle with an optimal protein-adjuvant formulation that combines targeting and controlled delivery for immunization...
This is a $1,500,000.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the Department of Health and Human Services, to Cure Systems LLC, a self-certified small disadvantaged business located in Newton, Massachusetts. The contract is for the research and development of "Vector-Based Delivery of HIV Broadly Neutralizing Antibodies," a specialized approach to developing advanced...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $33,273,522 cost-plus-fixed-fee definitive contract to Anivive Lifesciences Inc., a self-certified small disadvantaged business, to develop vaccine candidates for biodefense and emerging infectious diseases. This contract, awarded on June 7, 2024, is part of NIAID's Broad Agency Announcement (BAA) research program and has a completion date of June 1, 2026. The contract...
This federal contract award, with a total ceiling value of $2,250,744.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to the International AIDS Vaccine Initiative (IAVI), a global non-profit organization focused on HIV vaccine development. The purpose of the contract is to develop an optimized Phase 1 current Good Manufacturing Practice (cGMP) manufacturing process for lipid nanoparticle (LNP) fabrication that enables covalent coupling of an HIV-1 envelope...